
Louis Terriou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/440270/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Azacitidine for patients with Vacuoles, E1 Enzyme, Xâ€linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. British Journal of Haematology, 2022, 196, 969-974.	1.2	85
2	Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications. American Journal of Hematology, 2022, 97, 431-439.	2.0	7
3	Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1356-1364.e2.	2.0	2
4	Risk factors for severe neonatal thrombocytopenia in cases of maternal immune thrombocytopenia. Acta Paediatrica, International Journal of Paediatrics, 2022, 111, 985-991.	0.7	4
5	High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. American Journal of Hematology, 2021, 96, E43-E46.	2.0	11
6	Systemic Pulmonary Events Associated with Myelodysplastic Syndromes: A Retrospective Multicentre Study. Journal of Clinical Medicine, 2021, 10, 1162.	1.0	3
7	Correspondence in reference to the previously published Epub manuscript: immune thrombocytopenic purpura after SARSâ€CoVâ€2 vaccine. British Journal of Haematology, 2021, 194, e93-e95.	1.2	3
8	Safety of antiâ€SARSâ€CoVâ€2 vaccination for patients with immune thrombocytopenia. British Journal of Haematology, 2021, 195, 703-705.	1.2	20
9	Assessment of T-cell polarization onÂthe basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1110-1114.e2.	2.0	7
10	Clinical characteristics, management and outcome of COVIDâ€19â€associated immune thrombocytopenia: a French multicentre series. British Journal of Haematology, 2020, 190, e224-e229.	1.2	68
11	Epidemiology, clinical picture and longâ€ŧerm outcomes of <i>FIP1L1â€PDGFRA</i> â€positive myeloid neoplasm with eosinophilia: Data from 151 patients. American Journal of Hematology, 2020, 95, 1314-1323.	2.0	37
12	Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood, 2020, 136, 3056-3061.	0.6	42
13	Aplastic anemia related to thymoma: a survey on behalf of the French reference center of aplastic anemia and a review of the literature. Haematologica, 2020, 105, e333-e336.	1.7	7
14	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell Reports Medicine, 2020, 1, 100158.	3.3	18
15	Longâ€term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITPâ€ritux. American Journal of Hematology, 2019, 94, 1314-1324.	2.0	55
16	Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Clinical Rheumatology, 2019, 38, 1501-1511.	1.0	7
17	Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. Bone Marrow Transplantation, 2019, 54, 1161-1163.	1.3	16
18	Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review. Frontiers in Immunology, 2019, 10, 1489.	2.2	24

#	Article	IF	CITATIONS
19	Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia. Haematologica, 2019, 104, 256-262.	1.7	19
20	Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab. Journal of Clinical Rheumatology, 2019, 25, e40-e42.	0.5	3
21	Reply to Gilchrist et al. and to Musher. Clinical Infectious Diseases, 2018, 66, 637-638.	2.9	1
22	Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers. Haematologica, 2018, 103, e103-e105.	1.7	16
23	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica, 2018, 103, 212-220.	1.7	62
24	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 2018, 132, 2115-2124.	0.6	232
25	Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Advances, 2018, 2, 2176-2185.	2.5	65
26	Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology, 2018, 57, 1432-1438.	0.9	38
27	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica, 2018, 103, 1278-1287.	1.7	129
28	Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. Current Research in Translational Medicine, 2018, 66, 83-86.	1.2	9
29	Extensive levamisole-induced vasculitis. Clinical and Experimental Dermatology, 2017, 42, 413-415.	0.6	10
30	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. European Respiratory Journal, 2017, 49, 1700178.	3.1	9
31	Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmunity Reviews, 2017, 16, 743-749.	2.5	101
32	Hemophagocytic lymphohistiocytosis in patients with metastatic malignant melanoma. Melanoma Research, 2017, 27, 377-379.	0.6	6
33	Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial. Intensive Care Medicine, 2017, 43, 1613-1625.	3.9	26
34	Specific Polysaccharide Antibody Deficiency Revealed by Severe Bacterial Infections in Adulthood: A Report on 11 Cases. Clinical Infectious Diseases, 2017, 65, 328-331.	2.9	15
35	Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. Autoimmunity Reviews, 2017, 16, 903-910.	2.5	32
36	A randomized and doubleâ€blind controlled trial evaluating the safety and efficacy of rituximab for warm autoâ€immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology, 2017, 92, 23-27.	2.0	84

#	Article	IF	CITATIONS
37	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Advances, 2017, 1, 2742-2755.	2.5	151
38	Value of the Overall Pneumococcal Polysaccharide Response in the Diagnosis of Primary Humoral Immunodeficiencies. Frontiers in Immunology, 2017, 8, 1862.	2.2	26
39	TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature. Frontiers in Medicine, 2017, 4, 149.	1.2	30
40	OP0184â€Clinical Spectrum and Therapeutic Management of Systemic Lupus Erythematosus-Associated Macrophage Activation Syndrome. Data from A French Nationwide Study of 81 Episodes in 67 Adult Patients. Annals of the Rheumatic Diseases, 2016, 75, 126.2-127.	0.5	1
41	Reemergence of Splenectomy for ITP Second-line Treatment?. Annals of Surgery, 2016, 264, 772-777.	2.1	23
42	Are there any additional mechanisms for haemolysis in HELLP syndrome?. Thrombosis Research, 2016, 142, 40-43.	0.8	10
43	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood, 2016, 128, 1625-1630.	0.6	78
44	Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. American Journal of Hematology, 2016, 91, E499-E501.	2.0	20
45	Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus noâ€ŧreatment study. American Journal of Hematology, 2016, 91, 366-370.	2.0	110
46	Coexistence of rheumatoid arthritis and TEMPI syndrome: New insight in microangiogenic-related diseases. Joint Bone Spine, 2016, 83, 587-588.	0.8	10
47	A Multicenter Study Evaluating the Safety of Romiplostim at Maximal Dosage for Emergency Bleeding Situations in Immune Thrombocytopenia. Blood, 2016, 128, 2541-2541.	0.6	3
48	Thrombopoietin-Receptor Agonist in Systemic Lupus Erythematosus Associated Immune Thrombocytopenia: Results of the 16 Patients from the French Cohort. Blood, 2016, 128, 2542-2542.	0.6	3
49	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood, 2015, 126, 1885-1892.	0.6	76
50	Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood, 2015, 126, 1643-1650.	0.6	32
51	Persistent viral DNA detection in blood after primary herpes simplex 1 infection revealed by hepatitis with hemophagocytic syndrome. Journal of Clinical Virology, 2015, 69, 101-103.	1.6	6
52	CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica, 2015, 100, 1086-95.	1.7	37
53	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Investigational New Drugs, 2015, 33, 423-431.	1.2	33
54	Paroxysmal nocturnal hemoglobinuria (PNH) and T cell large granular lymphocyte (LGL) leukemia—an unusual association: another cause of cytopenia in PNH. Annals of Hematology, 2015, 94, 1759-1760.	0.8	7

#	Article	IF	CITATIONS
55	Radioimmunotherapy (90Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab. American Journal of Transplantation, 2015, 15, 1976-1981.	2.6	16
56	Cerebral Venous Thrombosis in Paroxysmal Nocturnal Hemoglobinuria. Medicine (United States), 2015, 94, e362.	0.4	30
57	Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine, 2015, 373, 1032-1039.	13.9	201
58	Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity. Blood, 2015, 126, 1985-1985.	0.6	1
59	A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimune Hemolytic Anemia in Adults. Blood, 2015, 126, 3338-3338.	0.6	1
60	A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists. Blood, 2015, 126, 3460-3460.	0.6	2
61	Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen. Bone Marrow Transplantation, 2014, 49, 1492-1497.	1.3	3
62	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2014, 311, 2490.	3.8	566
63	<i><scp>MYD</scp>88</i> L265P mutation contributes to the diagnosis of Bing Neel syndrome. British Journal of Haematology, 2014, 167, 506-513.	1.2	71
64	Detection of Non-Hodgkin's Lymphoma in ovarian cortex pieces during the process of cryopreservation. Journal of Assisted Reproduction and Genetics, 2014, 31, 1251-1255.	1.2	2
65	Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma. Clinical Cancer Research, 2014, 20, 3254-3260.	3.2	59
66	Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood, 2014, 124, 3228-3236.	0.6	142
67	The Lymphoid Variant of Hypereosinophilic Syndrome. Medicine (United States), 2014, 93, 255-266.	0.4	98
68	The Bruton's Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL). Blood, 2014, 124, 3328-3328.	0.6	7
69	Eculizumab Treatment Improves Outcomes of Pregnancy in Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2014, 124, 4393-4393.	0.6	2
70	The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL Journal of Clinical Oncology, 2014, 32, 8553-8553.	0.8	5
71	Temsirolimus in the treatment of mantle cell lymphoma. Current Opinion in Oncology, 2013, 25, S1-S12.	1.1	18
72	Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia, 2013, 27, 252-255.	3.3	42

#	Article	IF	CITATIONS
73	A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma. Blood, 2013, 122, 4397-4397.	0.6	9
74	Safety and Efficacy Of Rituximab In adult's Immune Thrombocytopenia (ITP) : Results After One-Year Of Follow-Up In 252 Patients From The Prospective French ITP-Ritux Registry. Blood, 2013, 122, 450-450.	0.6	2
75	Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens. Leukemia, 2012, 26, 2552-2554.	3.3	1
76	Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica, 2012, 97, 1666-1673.	1.7	110
77	Disseminated Infection Caused by <i>Francisella philomiragia</i> , France, 2014. Emerging Infectious Diseases, 2012, 21, 2260-2261.	2.0	17
78	Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients. Blood, 2012, 120, 3643-3643.	0.6	2
79	Traitement de maintenance des lymphomes malins non hodgkiniens. Oncologie, 2011, 13, 543-547.	0.2	0
80	Allogeneic Hematopoietic Stem Cell Transplantation in Paroxysmal Nocturnal Hemoglobinuria: A Transplant Versus No Transplant Matched Comparison Study On Behalf of the Severe Aplastic Anemia Working Party (SAA WP) of the European Group for Blood and Marrow Transplantation (EBMT) Group and the French Society of Hematology (SFH). Blood, 2011, 118, 2403-2403.	0.6	1
81	Nilotinib as Salvage Therapy In Patients with Chronic Graft Versus Host Disease. Blood, 2010, 116, 2329-2329.	0.6	0
82	C/EBPA methylation is common in T-ALL but not in MO AML. Blood, 2009, 113, 1864-1866.	0.6	6
83	Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood, 2009, 114, 719-722.	0.6	125
84	Recurrent in-frame insertion in C/EBPα TAD2 region is a polymorphism without prognostic value in AML. Leukemia, 2008, 22, 655-657.	3.3	12
85	Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood, 2008, 112, 3099-3106.	0.6	313
86	Allogeneic stem-cell transplantation with fludarabine and 2-Gy TBI-based conditioning regimen for chronic hematological malignancy: A study of 25 consecutive patients and a literature review. Leukemia and Lymphoma, 2007, 48, 321-329.	0.6	5
87	High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia, 2006, 20, 2067-2070.	3.3	64
88	Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens. Annals of Hematology, 2006, 85, 711-716.	0.8	11